YahooAugust 13, 2026 at 7:03 PM NY2 Months Ago
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
